Drug Information

Drug (ID: DG01904) and It's Reported Resistant Information

• Name: EAP Protocol
• Synonyms: EAP Protocol
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Gastric cancer [ICD-11: 2B72]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.R282L (c.845G>T)
• Sensitive Disease: Gastric adenocarcinoma [ICD-11: 2B72.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Stomach; N.A.
• Experiment for Molecule Alteration: Immunoblotting analysis
• Mechanism Description: The missense mutation p.R282L (c.845G>T) in gene TP53 cause the sensitivity of EAP Protocol by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.R175H (c.524G>A)
• Sensitive Disease: Gastric adenocarcinoma [ICD-11: 2B72.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Stomach; N.A.
• Experiment for Molecule Alteration: Immunoblotting analysis
• Mechanism Description: The missense mutation p.R175H (c.524G>A) in gene TP53 cause the sensitivity of EAP Protocol by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.R213P (c.638G>C)
• Sensitive Disease: Gastric adenocarcinoma [ICD-11: 2B72.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Stomach; N.A.
• Experiment for Molecule Alteration: Immunoblotting analysis
• Mechanism Description: The missense mutation p.R213P (c.638G>C) in gene TP53 cause the sensitivity of EAP Protocol by unusual activation of pro-survival pathway

References

• Ref 1: Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancerMol Pathol. 2003 Oct;56(5):286-92. doi: 10.1136/mp.56.5.286.